Atara Biotherapeutics News

Buy Rating Affirmed for Atara Biotherapeutics on Strong Pipeline and Financial Health

TipRanksMay 10 20:15

Atara Biotherapeutics | 10-Q: Quarterly report

Futu NewsMay 10 05:10 · Announcements

Atara Biotherapeutics Q1 2024 GAAP EPS $(0.23) Beats $(0.25) Estimate

Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.25) by 8 percent.

BenzingaMay 10 04:46

Earnings Flash (ATRA) ATARA BIOTHERAPEUTICS Reports Q1 Revenue $27.4M

04:04 PM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (ATRA) ATARA BIOTHERAPEUTICS Reports Q1 Revenue $27.4M

MT NewswiresMay 10 04:04

Atara Biotherapeutics 1Q Loss $31.8M >ATRA

Atara Biotherapeutics 1Q Loss $31.8M >ATRA

Dow JonesMay 10 04:01

Press Release: Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress

Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress Tab-cel(R) U.S. BLA on Track for Submission in Q2 2024 Initiation of ATA3219 Lupus Nephritis Study Expec

Dow JonesMay 10 04:01

Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress

Tab-cel U.S. BLA on Track for Submission in Q2 2024Initiation of ATA3219 Lupus Nephritis Study Expected in Q4 2024, with Initial Clinical Data Expected in H1 2025Initiation of New ATA3219 Cohort Witho

BusinesswireMay 10 04:01

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and

BusinesswireApr 6 04:01

Atara Biotherapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/01/2024 221.5% Stifel $4.8 → $2.3 Maintains Hold 11/10/2023 -30.11% Goldman Sachs $3 → $0.5 Maintains S

BenzingaApr 1 22:53

Stifel Adjusts Atara Biotherapeutics Price Target to $2.30 From $4.80, Maintains Hold Rating

Stifel Adjusts Atara Biotherapeutics Price Target to $2.30 From $4.80, Maintains Hold Rating.

MT NewswiresApr 1 21:27

Analysts Offer Insights on Healthcare Companies: Atara Biotherapeutics (ATRA) and Embecta Corporation (EMBC)

TipRanksApr 1 19:30

Analysts Offer Insights on Healthcare Companies: Affimed (AFMD) and Atara Biotherapeutics (ATRA)

TipRanksApr 1 10:20

Atara Biotherapeutics Board Member Decides Not to Seek Re-Election

Atara Biotherapeutics (ATRA) just unveiled an announcement.

TipRanksMar 30 04:43

Atara Biotherapeutics' Profitability Hinges on Partners' Success With Ebvallo Amid Market Challenges

TipRanksMar 29 14:00

Atara Biotherapeutics (ATRA) Gets a Buy From TD Cowen

TipRanksMar 29 04:06

Atara Biotherapeutics GAAP EPS of -$0.56 Misses by $0.03, Revenue of $4.25M Misses by $10.01M

Seeking AlphaMar 28 20:43

Earnings Flash (ATRA) ATARA BIOTHERAPEUTICS Reports Q4 Revenue $4.3M

08:30 AM EDT, 03/28/2024 (MT Newswires) -- Earnings Flash (ATRA) ATARA BIOTHERAPEUTICS Reports Q4 Revenue $4.3M

MT NewswiresMar 28 20:30

Atara Biotherapeutics 4Q Loss/Shr 56c >ATRA

Atara Biotherapeutics 4Q Loss/Shr 56c >ATRA

Dow JonesMar 28 20:30

Press Release: Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress Tab-cel(R) U.S. BLA on Track for Submission in Q2 2024 Following Positive Pre-BLA Meeting

Dow JonesMar 28 20:30

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress

Tab-cel U.S. BLA on Track for Submission in Q2 2024 Following Positive Pre-BLA MeetingAllogeneic CAR T Pipeline Expands Into Autoimmune Disease With Plans to Initiate an ATA3219 Lupus Nephritis Study

BusinesswireMar 28 20:30